Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates

NEXT STORY
GENFIT Provides Pipeline Update and Launch of New Clinical Programs
PREV STORY
Inhalation Anesthesia Market Size to Surpass US$ 24 Bn by 2030
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

New Analysis Shows Icosapent Ethyl (Vascepa®) Is Cost Effective and Offers Rare Finding of Better Outcomes at Lower Healthcare Costs When Used to Treat High-Risk Patients with Cardiovascular Disease or Diabetes and Other Risk Factors

author_avatar
NASDAQ Market News

European Antibacterial Personal Care Wipes Industry Forecast to 2027 – COVID-19 Impact and Regional Analysis

author_avatar
NASDAQ Market News

Nabriva Therapeutics Announces Submission of Marketing Authorization Application for Lefamulin to Treat Community-Acquired Pneumonia in Adults by European Medicines Agency

author_avatar
NASDAQ Market News